Method for determining the age of red blood cells

Glycated Hb was measured in reticulocytes (RNA-positive cells) and was correlated to a decrease in RNA fluorescence intensity in a Log-linear […]

Use of soluble trem-1 as a biomarker for assessing the risk of

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early […]

Use of vdac and lamp1 as markers for detecting pocked red blood cells

Counting vacuole-containing RBC (pocked-RBC) is a robust marker of defective spleen function but requires the expertise of fewer and fewer specialized […]

Methods for the diagnosis, prognosis and the treatment of transplant

Allogeneic kidney transplantation is a common transplant procedure and an optimal form of therapy for individuals who reach end-stage renal disease, […]

Use of ykl-40 as a biomarker for assessing functional outcome in acute

Today, more than 40% of acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT) will remain severely disabled at 3 months. The […]

Methods and kits for diagnosing cause of nephrotic syndrome and

The present invention describes the identification of a soluble glomerular permeability factor, anti-Vasorin (or anti-VASN) autoantibodies synthesized […]

Methods of determining whether a subject suffering from lupus

Systemic lupus erythematosus (SLE) is an autoimmune disease in which circulating immune complexes can cause different types of glomerulonephritis, […]

Cd1a as a biomarker and biotarget in cutaneous t-cell lymphomas

The present study of the regulatory T phenotype of Sézary cells led to the discovery of the expression of CD1a by Sézary cells. CD1a therefore […]

Methods and compositions for discriminating and treating stroke

Stroke is the second cause of death and the first cause of adult disability in industrialized countries. The goal of emergency therapy for acute […]

Method for discriminating mono-immunotherapy from combined

Combination therapy with anti-PD-1 and anti-CTLA-4 is now indicated in many cancers. It appears to be more effective than anti-PD-1 monotherapy, but […]